menu
    • menu
    [{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"Champignon","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Psilocybine","moa":"||5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dalriada Drug Discovery \/ Champignon","highestDevelopmentStatusID":"4","companyTruncated":"Dalriada Drug Discovery \/ Champignon"},{"orgOrder":0,"company":"Dalriada Drug Discovery","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Discovery","graph3":"Dalriada Drug Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Dalriada Drug Discovery \/ ATAI Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Dalriada Drug Discovery \/ ATAI Life Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Dalriada Drug Discovery

    Menu

    Dalriada Drug Discovery

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dalriada Drug Discovery

                            Canada arrow
                            RDD 2025
                            Not Confirmed

                            Dalriada Drug Discovery

                            Canada arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Discovery

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generati...

                            Details : This strategic collaboration with atai Life Sciences will focus on the creation of small molecule therapies by building on the mechanism of action of psychedelic and related compounds.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 27, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Discovery

                            Sponsor : ATAI Life Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dalriada Drug Discovery

                            Canada arrow
                            RDD 2025
                            Not Confirmed

                            Dalriada Drug Discovery

                            Canada arrow
                            RDD 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Champignon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advan...

                            Details : Champignon Brands has selected Toronto-based Dalriada Drug Discovery Inc.to advance its new chemical entity IP portfolio as it pertains to ketamine and psilocybin/psilicin molecular scaffolds.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            August 06, 2020

                            Lead Product(s) : Psilocybine,Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Champignon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth